Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study - Fassnacht, M; Berruti, A; Baudin, E (The Lancet Oncology, 2015)
doi:10.1016/S1470-2045(15)70081-1